Tenderwize
Wróć do wyszukiwania

Open-House non-exclusive rebate agreement for Sultamicillin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 551 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultamicillin (ATC-Code nach WHO: J01CR04)

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...

Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive rebate agreement for pharmaceutical products containing Sultamicillin (ATC J01CR04).
  • Open-House participation model with contract conclusion available to all interested pharmaceutical companies meeting the conditions.
Pokaż pełne podsumowanie

This is an Open-House framework-style pharmaceutical supply arrangement for Sultamicillin (CPV 33600000) led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis beyond the XML notice text. Submission is electronic via the portal communication function, not via the bidder tool, and the first participation deadline is 2026-02-03; the arrangement ends no later than 2028-02-29.

Ryzyka

The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...

Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product.

Administrative

  • Participation documents must be submitted as specified in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.
  • An 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' must be completed and submitted.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-House non-exclusive rebate agreement for Sultamicillin

Supply arrangement for non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for the active ingredient Sultamicillin (ATC J01CR04). The lot is an Open-House model: any interested pharmaceutical company may participate if it meets and accepts the stated conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Place of performance is Dresden, Germany, with performance covering Saxony and Thuringia as stated in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Feb 2026 - Feb 2028

Kategoria

Pharmaceutical products

Termin

Deadline Feb 29, 2028

Szczegóły zamówienia

Data publikacji
18 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
845306-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3